Fairvalue-Calculator Fairvalue-Calculator
EN DE

ImageneBio, Inc (IMA) Fair Value & Analysis

Healthcare · US · Market cap $67.7M

Price$6.01
Fair Value$53.12
Upside+783.9%
Quality95/100
Evidence: Low Range $39.84 – $66.40

Fair value as of: Jun 24, 2026

Analysis

ImageneBio, Inc (IMA) currently trades at $6.01, while our model-based Fair Value estimate is $53.12 — implying the stock looks roughly 783.9% undervalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: low) — always confirm before acting.

About the company

ImageneBio, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for patients with immunological, autoimmune and inflammatory diseases. Its lead product candidate includes IMG-007, a non-depleting anti-OX40 monoclonal antibody that binds to OX40 receptor on activated T cells to block receptor binding to OX40 ligand which is in Phase 1b/2a clinical trial. The company was formerly known as Ikena Oncology, Inc. and changed its name to ImageneBio, Inc. in July 2025. ImageneBio, Inc. is headquartered in San Diego, California.

Open the full interactive analysis →

Similar stocks

Vertex Pharmaceuticals Incorporated (VRTX34) -32% Regeneron Pharmaceuticals, Inc (REGN) -4% UCB SA (UCB) -23% argenx SE (ARGNF) -57% Samsung Biologics Co (207940) +1% Alnylam Pharmaceuticals, Inc (ALNY) -82%

Frequently asked questions

Is ImageneBio, Inc (IMA) undervalued?
As of Jun 24, 2026, our model estimates a fair value of $53.12 versus a price of $6.01 — about +784% (undervalued). Model-based estimate, not financial advice.
What is the fair value of IMA?
Our 21-model fair value for ImageneBio, Inc is $53.12 (as of Jun 24, 2026), built from audited fundamentals. The current price is $6.01.
What is the quality score of IMA?
ImageneBio, Inc has a Quality Score of 95/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.